Showing 5351-5360 of 8788 results for "".
- Escalier Biosciences' Doses First PsO Patient with ESR-114; Announces Clinical Advisory Boardhttps://practicaldermatology.com/news/escalier-biosciences-doses-first-patient-with-esr-114-announces-clinical-advisory-board/2457652/The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a significant milestone for Escalier as it validates o
- Castle Creek Pharmaceuticals Gets FDA Fast Track Designation for Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-gets-fda-fast-track-designation-for-diacerein-1-ointment-for-ebs/2457655/The U.S. Food & Drug Administration (FDA) granted fast track status to Castle Creek Pharmaceuticals, LLC’s diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS). "Fast Track designation is an
- FDA Approves Poteligeo for Cutaneous T-Cell Lymphomashttps://practicaldermatology.com/news/fda-approves-poteligeo-for-cutaneous-t-cell-lymphomas/2457657/The FDA approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with two types of cutaneous T-cell lymphoma (CTCL)—relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This a
- FDA Committee Recommends Approval of Paratek's Omadacyclinehttps://practicaldermatology.com/news/fda-committee-recommends-approval-of-parateks-omadacycline/2457656/The Antimicrobials Drug Advisory Committee of the FDA voted in favor of the approval of intravenous (IV) and oral omadacycline for the treatment of acute bacterial skin and skin structure infections (ABSSSI) (17-1) and community-acquired bacterial pneumonia (CABP) (14-4). Paratek Pharmaceuticals,
- Plastic Surgery Groups Issue Warning on the Risks of Brazilian Butt Liftshttps://practicaldermatology.com/news/plastic-surgery-groups-issue-warning-on-the-risks-of-brazilian-butt-lifts/2457659/Leading plastic surgery organizations are issuing a loud warning call about the risks associated with the popular Brazilian Butt Lift. “[The] procedure … has resulted in a mortality rate that is estimated to be as high as 1:3,000, greater than any other cosmetic surgery,&rdqu
- eRelevance Patient Engagement Survey Highlights Opportunities for Practiceshttps://practicaldermatology.com/news/erelevance-patient-engagement-survey-highlights-opportunities-for-practices/2457660/eRelevance Corporation, the leading provider of consumer engagement services for small- to medium-size businesses (SMBs) has released
- IRB Approval Means BioPharmX To Move Ahead on Phase 2 Trial of BPX-04 for Rosaceahttps://practicaldermatology.com/news/irb-approval-means-biopharmx-to-move-ahead-on-phase-2-trial-of-bpx-04-for-rosacea/2457665/BioPharmX Corporation has received Institutional Review Board approval for its phase 2 study of BPX-04 for the treatment of papulopustular rosacea. Based on data from its open-label feasibility study which assessed tolera
- Dermatologist Named a Finalist for Inaugural FNIH Trailblazer Prize for Clinician-Scientistshttps://practicaldermatology.com/news/dermatologist-named-a-finalist-for-inaugural-fnih-trailblazer-prize-for-clinician-scientists/2457663/An oncodermatologist is in the running for the Foundation for the National Institutes of Health (FNIH) inaugural Trailblazer Prize for Clinician-Scientists. The three finalists are Daniel Bauer, MD, PhD, Harvard Medical School, Jaehyuk Choi, MD, PhD, Feinberg School of Medicine, North
- Castle Biosciences' DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence, Metastasishttps://practicaldermatology.com/news/castle-biosciences-decisiondx-melanoma-test-improved-ajcc-based-risk-prediction-for-melanoma-recurrence-metastasis/2457664/Castle Biosciences, Inc’s. DecisionDx®-Melanoma test improved risk prediction beyond that using American Joint Committee on Cancer (AJCC) based staging, according to a new study presented at the DERM2018 NP/PA CME Conference held in Las Veg
- LEO Pharma to Acquire Bayer Prescription Dermatology Businesshttps://practicaldermatology.com/news/leo-pharma-to-acquire-bayer-prescription-dermatology-business/2457666/LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections, and rosacea and a range of topical steroids with an annual turnover in 2017 o